General Practice · Full case

Analgesia in Primary Care

NICE NG193 / WHO ladderPain type-ledOpioid stewardship
AN
Analgesia in Primary Care · Clinical Reasoning Framework v2
GP & SCA · acute vs chronic · nociceptive vs neuropathic vs primary pain · WHO ladder · NICE NG193 · opioid stewardship · deprescribing · the difficult conversation
Name the pain type firstTreatment follows the mechanism: NOCICEPTIVE (tissue damage — responds to paracetamol/NSAID/the WHO ladder), NEUROPATHIC (burning/shooting, allodynia — responds to amitriptyline/duloxetine/gabapentinoids, NOT standard analgesics), or CHRONIC PRIMARY PAIN (pain as the condition itself — NG193). Reaching for "stronger painkillers" without naming the type fails
Acute: WHO ladder, time-limitedFor acute nociceptive pain: step up the WHO ladder — paracetamol ± NSAID (lowest dose/shortest course, gastroprotection & renal/CV caution), then weak then strong opioids for short, defined courses with a stop date. Topical NSAIDs first for localised musculoskeletal pain
🟣 Chronic primary pain (NG193)For chronic primary pain, NICE NG193 recommends AGAINST starting paracetamol, NSAIDs, opioids, gabapentinoids or benzodiazepines — they don't help and cause harm. Offer instead: exercise, CBT/ACT, acupuncture, and (off-label) an antidepressant (e.g. duloxetine/amitriptyline) after shared discussion
Opioids: poor for chronic painOpioids have little benefit in chronic non-cancer pain and substantial harm (dependence, hyperalgesia, falls, overdose, hormonal/immune effects). Avoid escalating; doses towards ~120mg morphine-equivalent/day rarely add benefit and substantially increase harm. Review and deprescribe
Gabapentinoids = controlled drugsPregabalin/gabapentin are controlled drugs with misuse/dependence potential, especially with opioids (additive respiratory depression and overdose). Use only for neuropathic pain, review regularly, and never co-prescribe casually with opioids
Deprescribe collaborativelyReducing opioids/gabapentinoids that aren't working is active care — gradual, agreed, with support, addressing the function/mood drivers and the fear of increased pain (withdrawal-mediated). Don't stop abruptly; don't abandon. Set functional goals, not just pain scores
Treat the cause & the personAnalgesia is an adjunct: find and treat the cause, screen red flags, address mood/sleep/function and the biopsychosocial picture. Chronic pain is rarely "fixed" by a tablet; the goal is improved function and quality of life, supported self-management, and realistic expectations
The difficult conversationPatients on long-term opioids who feel they help, and request more, are common and challenging. Validate the pain and distress, avoid blame, explain the evidence honestly, and partner on a plan — coercion or abrupt stopping drives harm and disengagement
A 49-year-old man on escalating opioids for chronic back pain that "still doesn't touch it", asking for a stronger dose — whose function and mood are worsening
📋 Clinical Stem — Analgesia in Primary Care
Neil Brandon, 49, has had chronic low back pain for 4 years with no red flags and normal imaging. He's been on increasing doses of opioids (now a high morphine-equivalent dose) plus a gabapentinoid, and attends asking for a stronger dose because the pain "still doesn't touch it". Despite the medication, his function is worse — he's stopped working and exercising, sleeps badly, and his mood is low. He's frustrated, feels no one takes his pain seriously, and is frightened that without more medication he won't cope. He drinks more than he used to. He's never been offered exercise therapy, psychological support or a clear explanation of his pain.
This stem tests rational analgesia and opioid stewardship: recognising chronic primary/non-cancer back pain where escalating opioids and gabapentinoids provide little benefit and cause harm (worsening function, mood, sleep, dependence, overdose risk — heightened by the alcohol and the opioid+gabapentinoid combination); naming the pain type and applying the right guideline — NICE NG193 for the assessment and for chronic primary pain (recommends against starting these drugs; exercise, psychological therapy and possibly an antidepressant), used alongside NG59 because this is low back pain (no opioids for chronic low back pain, no gabapentinoids, and no antidepressants for the back pain itself — though depression, if present, is treated in its own right); validating the patient's genuine pain and distress while honestly explaining the evidence; planning a collaborative, gradual deprescribing of opioids/gabapentinoid with support, functional goals, and treatment of the mood/sleep/alcohol drivers; and avoiding both uncritical dose escalation and abrupt, punitive stopping. The SCA challenge is the difficult conversation — declining to escalate, and proposing a different, evidence-based path, without the patient feeling dismissed or abandoned.
Scenario A — Chronic pain, opioid escalation request (this stem) Validate; don't escalate; name the pain type (NG193); offer exercise/psychological therapy ± antidepressant; collaborative deprescribing of opioids/gabapentinoid; treat mood/sleep/alcohol; functional goals.
Scenario B — Acute nociceptive pain WHO ladder, time-limited: paracetamol ± topical/oral NSAID (cautions), short opioid course with a stop date; treat the cause.
Scenario C — Neuropathic pain Burning/shooting/allodynia → amitriptyline/duloxetine/gabapentinoid (not standard analgesics); treat the cause; review.
Scenario D — Cancer / palliative pain Different paradigm — WHO ladder including strong opioids titrated to effect, anticipatory care, specialist palliative support.
Scenario E — Red-flag pain New severe/atypical pain with red flags (cauda equina, fracture, malignancy, infection) → don't just analgese — investigate/refer urgently.
Key variables to adapt for Acute vs chronic; pain type (nociceptive/neuropathic/primary); WHO ladder vs NG193; opioid/gabapentinoid stewardship & deprescribing; high-risk combinations (opioid+gabapentinoid+alcohol); function/mood/sleep drivers; red flags; cancer/palliative paradigm; the difficult conversation & shared decisions.
Steps:
1
Step 1
History — Validate & Name the Pain Type · Function/Mood · Meds & Risk · Red Flags · ICE
▲collapse
The history must validate the pain as real, name the pain type (which determines treatment), assess the impact on function and mood (the real targets), review the current medication and its risks, and screen red flags. Neil's escalating opioids with worsening function is the signature of chronic pain mismanaged with the wrong tools — the consultation's job is to redirect, compassionately.
🎓 SCA framing — validate the pain, redirect the treatment
"I don't doubt your pain is real and exhausting — and I can see the medication isn't giving you your life back. I'm not going to dismiss you. But I'd be doing you a disservice to just add more of something that isn't working and is causing harm. Let me explain a different approach that genuinely helps."
Declining to escalate without validating and offering an alternative will fail. Naming the pain as real, the medication as ineffective/harmful, and proposing an evidence-based path is the skill.
1A — Pain type, function, medication and red flags
QuestionWhy it mattersActionChanges what?
🟢 OPEN QUESTION"Tell me about the pain and what it's doing to your life — not just how it feels, but what it stops you doing." Centres function and the lived experience, and lets the pain type emerge. Neil's 4-year back pain with worsening function despite escalating opioids is chronic pain where the medication is part of the problem. The functional and mood impact — not the pain score — are the meaningful targets.In SCA: assessing function/mood and naming the pain type, rather than reaching for a dose, is the core reasoning. Function/mood are the targets, not the dose
Pain type"Is it an aching/throbbing pain, or burning/shooting with numbness or sensitivity to touch? Is there an ongoing injury, or has the pain become the problem itself?"Naming the mechanism dictates treatment: nociceptive → WHO ladder; neuropathic → amitriptyline/duloxetine/gabapentinoid; chronic primary pain (pain as the condition, no ongoing tissue damage) → NG193 (exercise, psychological therapy, antidepressant; NOT escalating analgesics). Neil's persistent non-specific back pain behaves like this, but because it is low back pain NICE NG193 says to use it alongside NG59 — the same message on opioids and gabapentinoids, but NG59 does not recommend antidepressants or acupuncture for the back pain itself. The wrong tool for the type is why he's not improving.Pain type → the right treatment paradigm.Type → WHO ladder vs NG193 vs neuropathic agents
Current medication & effect"What are you taking, how much, and honestly — how much does it actually help your function, not just the score?"High-dose opioids + a gabapentinoid with worsening function is evidence of harm without benefit (opioid-induced hyperalgesia, sedation, dependence). The honest question — does it help you DO more? — often reveals it doesn't, which is the lever for change.No functional benefit → don't escalate; plan deprescribing.No benefit → review/deprescribe, not escalate
🚩 Risk & high-risk combinations"How much alcohol are you drinking? Any drowsiness, near-overdoses, or running out early? Any low mood or thoughts of self-harm?"The safety core. Opioid + gabapentinoid + alcohol (Neil drinks more) is a dangerous, overdose-prone combination (additive respiratory depression). Low mood and self-harm risk are common in chronic pain and raise overdose risk. Assess and address — and consider naloxone.Opioid+gabapentinoid+alcohol → overdose risk; mood/self-harm → assess/treat.High-risk combo/mood → safety + naloxone
🚩 Red flags / re-examine the cause"Has the pain changed — any new severe pain, leg weakness, bladder/bowel problems, weight loss, fever, or night pain?"Don't let "chronic pain" mask a new serious cause. New or changed pain with red flags (cauda equina, fracture, malignancy, infection) needs investigation/referral, not just analgesia. Re-screening is part of safe ongoing pain care.New red flags → investigate/refer, don't just analgese.Red flags → urgent assessment
Drivers & what's been tried"How's your sleep, mood, work and activity? Have you ever been offered exercise therapy, psychological support, or a clear explanation of your pain?"Chronic pain is biopsychosocial: sleep, mood, deconditioning, work loss and the meaning of pain all amplify it. Neil has had none of the evidence-based non-drug therapies — the very things that help. Identifying the gaps shapes the plan.Untreated drivers/no non-drug therapy → offer exercise/CBT/explanation.Offer exercise/psychological therapy; treat mood/sleep
1B — Red flags
🚨

Red Flags — the harms of analgesia and the missed cause

Red flagWhy it mattersAction
Opioid + gabapentinoid + alcohol/benzodiazepineAdditive respiratory depression and overdose.Address combination; take-home naloxone; deprescribe; reduce alcohol
Escalating opioids with worsening function (hyperalgesia)Harm without benefit; dependence; falls; hormonal/immune effects.Don't escalate; review & deprescribe; non-drug therapies
New/changed pain with red flags (cauda equina, fracture, malignancy, infection)Serious cause masked as "chronic pain".Investigate/refer urgently; don't just analgese
Low mood / self-harm / overdose ideationCommon in chronic pain; raises overdose risk.Assess/treat mood; safety plan; mental-health support
Dependence / running out early / aberrant useOpioid/gabapentinoid dependence.Non-judgmental; structured deprescribing; specialist support if needed
NSAID harms (GI/renal/CV), paracetamol in liver diseaseAnalgesics themselves cause harm.Lowest dose/shortest course; gastroprotection; check renal/hepatic
1C — ICE
💭 Ideas
"What do you feel the medication is doing for you — and what do you think would help most?"
Neil believes stronger opioids are the answer and fears coping without them. Surfacing this lets you explore, honestly, whether they're actually helping his function, and to introduce the evidence and a different model of pain without simply contradicting him.
😟 Concerns
"What are you most worried about — the pain, not being believed, or not coping without more medication?"
His concerns — not being taken seriously, and fear of withdrawal/uncontrolled pain — are exactly what derail these consultations. Naming and addressing them (validation, a supported plan, no abandonment) is what makes change possible.
🎯 Expectations
"You came hoping for a stronger dose — can I be honest about why that won't help, and what will?"
He expects dose escalation. Naming this lets you decline it transparently while offering a credible alternative (exercise, psychological therapy, treating mood/sleep, careful deprescribing with support) — so he leaves with a plan, not a refusal.
1D — Psychosocial context
🤝 Real pain, the wrong tools, and the conversation everyone dreads

Chronic pain is real, disabling and isolating — and for years the reflexive response was escalating opioids, which we now know rarely help and frequently harm, leaving patients more disabled, dependent and at risk. The hardest, most valuable consultation in pain care is declining to escalate while keeping the person on side: validating their suffering, owning that the system (not the patient) reached for the wrong tools, explaining the evidence honestly, and offering a genuinely better path — exercise, psychological support, treating mood and sleep, and careful, supported deprescribing — without ever abandoning them.

✅ Validate first

The pain is real; the patient is not to blame.

"Your pain is real and I believe you — and none of this is your fault. The medication you were given seemed sensible at the time, but the evidence has moved on and it's not serving you well."
📉 Why not more opioids

Explain hyperalgesia/harm honestly.

"Strong painkillers actually do very little for long-term pain, and over time they can make the nervous system more sensitive — so more medication can mean more pain and less life, which is what's happened."
🏃 The better path

Offer credible, evidence-based alternatives.

"The things that genuinely help long-term pain are movement built up gradually, support to manage the impact, and treating your sleep and mood — and I can get you those, which you've never been offered."
🤝 No abandonment

Reassure you'll support the change.

"I'm not going to stop anything suddenly or leave you to struggle. We'll reduce slowly, together, while we build up the things that work — and I'll be here throughout."
1E — Psychosocial context: the person behind the prescription
🤝
Neil — four years of pain, a lost job, a shrinking life, and a prescription that became part of the problem
NICE NG193 asks for an assessment of all chronic pain that looks beyond the pain score: how the pain affects the person's life, work, relationships, sleep and mood, what they believe about it, and what they hope for. For Neil these questions are not optional extras — they are where the treatment targets actually sit. Each card below is something to ask about, why it matters, and a phrase to use.
💼
Work, money and identity

Neil has stopped working. Worklessness in chronic pain is both a consequence and a cause: loss of structure, income, purpose and social contact all amplify pain and low mood, and the longer someone is off, the harder the return. Benefits assessments and money worries add a constant background stress, and some patients fear that improving will threaten their income or be seen as proof they were "putting it on".

Ask what his job was, what he misses, and whether a phased or adjusted return is imaginable. NICE NG59 recommends promoting and facilitating return to work or normal activities for people with low back pain.

"What did you do for work, and what do you miss most about it? I'd like part of our plan to be about getting some of that back — not straight away, but step by step."
🏠
Family, relationships and carers

Partners and families often become carers, take over tasks and — out of kindness — encourage rest. Irritability from pain, withdrawal effects between doses, sedation and alcohol strain relationships. Family members are also the people who will find him if he overdoses, so they need to know about naloxone and the signs of too much medication.

Ask who is at home, how they are coping, and whether anyone else in the household takes medicines that could be shared or taken by mistake (including children and visitors).

"Who's at home with you, and how are they finding things? Would it help if someone came with you next time, so they hear the plan too — and know what to do if you ever became very drowsy?"
🍺
Alcohol, sleep and coping

Neil drinks more than he used to. Alcohol is often self-medication for pain, sleep and low mood, and with opioids and a gabapentinoid it multiplies the risk of respiratory depression (MHRA). It also worsens sleep architecture, mood and liver safety for paracetamol. Ask non-judgementally and quantify (AUDIT-C), and ask what else he uses to cope — including over-the-counter codeine, someone else's tablets, or cannabis.

"Lots of people in pain find a drink takes the edge off or helps them sleep — I'm not judging. Can you tell me roughly how much you're having in a typical week? It matters because of how it mixes with your tablets."
😔
Mood, hopelessness and safety

Low mood is common in chronic pain and runs both ways: pain worsens mood and low mood amplifies pain. Hopelessness, access to a large supply of opioids and gabapentinoids, and alcohol together make a direct question about self-harm and suicidal thoughts essential — asking does not increase risk. Screen formally (PHQ-9, GAD-7) and ask directly.

"When pain goes on this long, people sometimes feel it's never going to get better, or even that they'd rather not be here. Have you had thoughts like that? I ask everyone in your situation, because it matters for how we keep you safe."
🧠
Beliefs about pain and medication

Neil's model is "more pain means more damage, so I need stronger painkillers". Fear that movement causes harm (fear-avoidance) and catastrophising predict disability more strongly than scan findings. He may also fear that reducing medication will unleash unbearable pain, not knowing that withdrawal symptoms and opioid-induced hyperalgesia can make pain feel worse on high doses and that many people feel better as doses fall (site opioid protocol, Opioids Aware principles).

"What do you think is going on in your back? And what do you think would happen if we slowly lowered the tablets? I ask because what people believe about their pain makes a real difference to what helps."
⚖️
Past experiences with services

Neil feels no one takes his pain seriously. Previous consultations may have left him feeling dismissed, or accused of drug-seeking. Each dose increase was likely offered in good faith but without a plan to review. Acknowledging the system's part — rather than blaming him — is often what unlocks engagement. Check who prescribes (one prescriber, one pharmacy), and whether he has had pain clinic, physiotherapy or psychology input before.

"It sounds like you've had to fight to be believed, and that the answer each time was a stronger tablet. That's not your fault. I'd like to do things differently with you, and I'll be straight with you all the way through."
1F — Structured analgesic history: count the real dose and the real risk
Ask / checkWhyChanges what?
Every analgesic, dose and how he actually takes it"Talk me through a typical day — what do you take, when, and do you ever take extra or save some?"The prescribed dose and the taken dose often differ. Stockpiling, "saving the top-ups" and running out early are all common. Convert everything to a total oral morphine equivalent (OME) using the Opioids Aware conversion guidance; local high-dose opioid guidance advises caution above 50 mg/day OME and not escalating towards about 120 mg/day, where harm increases substantially without added benefit.Total OME → taper plan, specialist threshold
Over-the-counter and borrowed medicines"Do you buy anything from the chemist, or ever use anyone else's tablets?"OTC codeine combinations (co-codamol 8/500, codeine with ibuprofen) are sold in packs of no more than 32 tablets and labelled for three days' use only because of addiction risk (MHRA, 2009). Duplicate paracetamol from OTC products is a common route to unintentional overdose.Duplicate paracetamol / hidden opioid → counsel, rationalise
Other sedatives"Anything for sleep, nerves or anxiety — prescribed or not?"Benzodiazepines and Z-drugs with opioids cause potentially fatal respiratory depression — only co-prescribe if there is no alternative (MHRA DSU, March 2020). Gabapentinoids also cause respiratory depression, including without opioids (MHRA DSU gabapentin October 2017; pregabalin February 2021).CNS-depressant stack → deprescribing priority, naloxone
Dependence and addiction features"Do you ever feel you need them even when the pain is OK? Any cravings, or taking more than planned?"Physical dependence (tolerance, withdrawal) is expected with long-term use; addiction (craving, loss of control, use despite harm) needs drug-service input alongside primary care. MHRA (September 2020) advises that long-term opioid use for non-cancer pain (longer than 3 months) carries an increased risk of dependence and addiction, even at therapeutic doses.Addiction features → drug & alcohol service alongside GP
Physical harms"How are your bowels? Energy, sex drive? Any falls or feeling foggy?"Constipation, sedation, cognitive slowing, falls and opioid-induced hypogonadism (fatigue, low libido, erectile dysfunction) are common on long-term opioids and are further reasons to reduce. Snoring or witnessed apnoeas raise concern about sleep-disordered breathing, which adds to respiratory depression risk.Consider testosterone, falls review
Driving and work safety"Do you drive or operate machinery? Ever felt drowsy doing so?"It is an offence to drive with certain specified drugs (including morphine) above set limits, or while impaired by any drug; there is a medical defence only if the drug is taken as prescribed and driving is not impaired. Advise not to drive if drowsy, after starting or changing doses, or with alcohol.Driving advice documented
🎓 SCA Checkpoint — Step 1TasksRelating to OthersGlobal Skills
Key phrases that score
"Is it aching tissue pain, burning nerve pain, or has the pain itself become the problem?" — names the type.
"Does the medication help you DO more, honestly?" — function over score.
"Opioids plus the gabapentinoid plus alcohol is a risky mix — let's keep you safe." — high-risk combination.
Deductions
  • Escalating opioids without naming the pain type / assessing function
  • Missing the high-risk combination (opioid+gabapentinoid+alcohol)/mood/self-harm
  • Not re-screening red flags
  • Declining the request without validation or an alternative (patient feels dismissed)
🔴 Red
Escalates opioids; or refuses bluntly with no validation/alternative; pain type/function/risk not assessed; red flags missed
🟠 Amber
Validates; names pain type; declines escalation; some risk assessment; alternatives/deprescribing vague; ICE partial
🟢 Green
Validates & names pain type; function/mood assessed; high-risk combo addressed; declines escalation with NG193 alternatives + supported deprescribing; ICE all three; safety-net
2
Step 2
Triage — Red-Flag Pain · Overdose Risk · Acute vs Chronic Pathways
▲collapse
Triage separates pain that needs urgent investigation (red flags) and the patient at acute overdose risk from the routine acute-vs-chronic analgesic decision.
🔴 Urgent

Investigate / safety

Don't just analgese
  • Red-flag painCauda equina/fracture/malignancy/infection → investigate/refer
  • Overdose risk / dangerous comboOpioid+gabapentinoid+alcohol → safety, naloxone
  • Self-harm / severe moodMental-health support
🟠 Chronic

NG193 path

Right tools
  • Chronic primary painExercise/CBT/antidepressant; NOT opioids/gabapentinoids
  • On long-term opioids w/o benefitSupported deprescribing
  • NeuropathicAmitriptyline/duloxetine/gabapentinoid
🟢 Acute

WHO ladder

Time-limited
  • Acute nociceptiveParacetamol ± NSAID; short opioid w/ stop date
  • Localised MSKTopical NSAID first
  • Cancer painWHO ladder + palliative input
🎓 SCA Checkpoint — Step 2Tasks
Triage rationale
"There's nothing to suggest a new dangerous cause, which is reassuring — so this is long-term pain that needs a different approach than stronger opioids, plus we need to make the current mix safer."
Deductions
  • Treating red-flag pain as routine
  • Ignoring overdose risk
3
Step 3
Examination — Re-examine the Cause · Function · Mood · Sedation/Overdose Signs
▲collapse
Examination re-checks for a serious or treatable cause (especially if the pain has changed), assesses function and the impact of the pain, and looks for signs of medication harm (sedation, overdose risk) — and screens mood.
🔎 Cause & function
CheckWhy
Focused examination of the painful areaRe-screen red flags; treatable cause; neuro exam (back/limb).
Function / mobilityWhat he can do; deconditioning.
Mood / sleepDepression/anxiety; the amplifiers.
Neuropathic signsAllodynia, sensory change — directs treatment.
⚕️ Medication harm
CheckWhy
Sedation / cognitionOpioid/gabapentinoid effects; overdose risk.
Signs of opioid effectsConstipation, hypogonadism, falls.
Alcohol/substance signsCo-use; liver.
General/physical healthComorbidity affecting analgesic choice.
🎓 SCA Checkpoint — Step 3TasksGlobal Skills
Narration that scores
"I'll examine your back and legs to make sure nothing's changed or been missed, check how you're moving, and look at how the medication might be affecting you — and ask about your mood and sleep, which really matter in pain."
Deductions
  • Not re-examining when pain has changed
  • Not assessing function/mood/sedation
4
Step 4
Investigations — Only If Indicated · Bloods Before Drugs · Review the Record
▲collapse
Chronic primary pain rarely needs (re-)investigation; tests are for new red flags, to check organ function before/with analgesics, and to review the prescribing record. Resist re-scanning chronic back pain without a new indication.
🧪 When indicated
TestWhy
Bloods (renal/hepatic, FBC)Before NSAIDs/paracetamol; alcohol effects; general health.
ImagingOnly for NEW red flags / changed pain — not routine re-scanning.
Mood/risk toolsDepression/anxiety; overdose risk.
Record review / MED calculationMorphine-equivalent dose; prescribing pattern; supply intervals.
🚫 Avoid

Routine re-imaging of chronic back pain with no new red flags (incidental findings drive harm and over-medicalisation).

Investigations as a substitute for the harder conversation about deprescribing and non-drug care.

🎓 SCA Checkpoint — Step 4Tasks
Key reasoning
"Your scans were normal and nothing's changed to need repeating — re-scanning often finds harmless things that lead to more worry and treatment. I'll check some bloods, look at your prescribing record, and focus on what actually helps."
Deductions
  • Routine re-imaging without a new indication
  • Not calculating the morphine-equivalent dose / reviewing the record
5
Step 5
Formulation — Pain Type → Treatment Paradigm
▲collapse
The "diagnosis" is the pain type and the right paradigm — matched to the person, their function and their risks.
Pain typeTreatment paradigm
Acute nociceptiveWHO ladder, time-limited; topical NSAID for localised MSK; treat the cause.
NeuropathicAmitriptyline/duloxetine/gabapentinoid (not standard analgesics); treat the cause.
Chronic primary painNG193: exercise, psychological therapy (CBT/ACT), acupuncture, consider an antidepressant; do not start opioids/gabapentinoids/NSAIDs/paracetamol/benzodiazepines; deprescribe.
Chronic low back pain (Neil)NG59 alongside NG193: group exercise programme; manual therapy only within a package that includes exercise; promote return to work and normal activities. (NG59's psychological therapy and combined physical–psychological programme recommendations were withdrawn in July 2026 because they relied partly on retracted evidence; ACT/CBT remains an NG193 option where the pain behaves as chronic primary pain.) Do NOT offer opioids for chronic LBP, gabapentinoids, SSRIs/SNRIs/TCAs for the back pain, paracetamol alone, or acupuncture. Oral NSAID may be considered at the lowest effective dose for the shortest time. Treat coexisting depression in its own right.
Cancer / palliativeWHO ladder incl. titrated strong opioids; specialist palliative care.
Mixed / red-flagTreat the cause first; combine paradigms; investigate red flags.

🚩 The wrong paradigm is the problem

Neil's formulation is chronic non-specific low back pain with the features of chronic primary pain, mismanaged with escalating opioids and a gabapentinoid that have worsened his function, mood and risk (compounded by alcohol). The plan: validate; decline escalation; apply NG193 assessment principles with NG59 for the back pain (exercise, with ACT/CBT for pain under NG193 for the chronic-primary-pain features; no opioids, gabapentinoids or antidepressants for the back pain itself); assess his low mood formally and, if he has depression, treat it in its own right — which may include an antidepressant such as duloxetine chosen with the pain in mind; collaboratively and gradually deprescribe the opioids and gabapentinoid with support; treat his mood, sleep and alcohol; set functional goals; provide naloxone and safety-net — never abruptly stopping or abandoning.

🎓 SCA Checkpoint — Step 5Tasks
Explaining the plan
"This is the kind of long-term pain where the painkillers we'd reach for actually don't help and cause harm. The evidence points to movement, support for managing it, and treating your sleep and mood — and slowly easing down the strong medication. I'll set that up and support you through it."
Deductions
  • Applying the WHO ladder/opioids to chronic primary pain
  • Not naming the right paradigm (NG193)
6
Step 6
Referral — Pain Service · Physio/Psychology · Drug Service · Mental Health
▲collapse
Referral provides the non-drug therapies and the support for deprescribing: physiotherapy/pain-management programmes, psychological therapy, the pain clinic for complex cases, drug services for dependence, and mental-health support — with the GP coordinating.
ReferralWho / whenRole
Physiotherapy / exercise programmeGraded exercise — cornerstone of chronic-pain management.First-line
Psychological therapy (CBT/ACT)Pain-management, mood, coping.First-line
Pain clinic / pain-management programmeComplex/refractory pain; multidisciplinary; deprescribing support.Complex
Drug & alcohol serviceOpioid/gabapentinoid dependence; alcohol.Dependence
Mental healthDepression/anxiety/self-harm risk.If risk
🎓 SCA Checkpoint — Step 6Tasks
Offering the real treatment
"I'll refer you for physiotherapy and a pain-management programme — the things that actually help — and get you support for your mood and the drinking, and we'll ease the medication down together with help from the team."
Deductions
  • Declining opioids without offering the alternative therapies
  • Not supporting deprescribing / dependence
7
Step 7
Management — Expectation · Goals · Non-Drug Care · Prescribing Guide · Drug Cards · Psychosocial · Follow-Up · Monitoring · Safety-Net
▲collapse
Management matches the analgesic to the pain type, declines harmful escalation, deprescribes opioids/gabapentinoids gradually and collaboratively with support, treats the drivers (mood, sleep, alcohol), sets functional goals, provides harm reduction (naloxone) and safety-nets — keeping the patient engaged throughout.
💊 Rational analgesia & deprescribing
ElementDetail
Acute nociceptiveWHO ladder, time-limited; topical NSAID for localised MSK; stop dates.
NeuropathicAmitriptyline/duloxetine/gabapentinoid; review.
Chronic primary painNG193: exercise, CBT/ACT, consider antidepressant; do NOT start or escalate opioids/gabapentinoids.
Chronic low back pain (Neil)NG59 with NG193: exercise; ACT/CBT via NG193 if chronic primary pain features; no opioids, gabapentinoids or antidepressants for the back pain; treat depression if present.
DeprescribeGradual, agreed, supported reduction of opioids/gabapentinoid; never abrupt; address withdrawal fear.
Harm reductionTake-home naloxone; reduce alcohol; avoid co-prescribing combinations.
🎯 Drivers, goals & support
ElementDetail
Functional goalsWalking, work, sleep — measure progress by function, not pain score.
Treat mood & sleepDepression/anxiety, sleep hygiene; the amplifiers.
Self-management & educationPacing, understanding pain, peer support.
Safety-net & reviewRed-flag advice; overdose advice; regular review; don't abandon.
Continuity & partnershipSame GP; relapse/setbacks expected; keep engaged.
7A — Address the patient's expectation first: validate → explain → negotiate
🤝
Neil expects a stronger dose. Don't dismiss it — acknowledge it, explain why it won't help, then agree a plan he can live with
1
Validate — name the request and the distress behind it

Neil's request is logical from where he sits: every previous increase was offered as the answer, and the pain is still there. Behind it sit exhaustion, fear of withdrawal and of not coping, and the experience of not being believed. Naming the request out loud, and the feeling behind it, shows you have heard him before you say anything he does not want to hear.

"You've come in hoping for a stronger dose, because the pain is still wrecking your days even on all these tablets. That makes complete sense — you've been told before that a higher dose was the answer. I believe the pain is real, and I want to help."
2
Explain — share the evidence honestly, in his terms

The key messages: opioids help little in long-term non-cancer pain, and NICE NG59 advises against them for chronic low back pain; towards about 120 mg/day morphine-equivalent, harm rises substantially without extra benefit (local high-dose opioid guidance); the gabapentinoid is not recommended for back pain (NG59); and the combination with alcohol risks stopping his breathing (MHRA). Link the evidence to his own experience — doses have gone up, and his life has got smaller.

"Here's what's become clear over the last few years: for long-term back pain, strong painkillers give very little benefit, and as the dose goes up they can make the nerves more sensitive, sap your energy and mood, and become dangerous with alcohol. Honestly — has each increase given you more life, or less?"
3
Negotiate — offer something real today

A refusal on its own is abandonment. Neil should leave with: a referral for exercise-based rehabilitation (with psychological therapy for pain — ACT or CBT — or a pain-management programme where available), a mood assessment and treatment offer, alcohol support, take-home naloxone and safety advice, an agreed start date and pace for a slow reduction he controls, and a follow-up booked with the same clinician. He sets the pace; you hold the direction.

"I'm not going to increase the dose, and I'm not going to stop anything suddenly either. What I'd like is this: we get you into a programme that actually helps back pain, we look after your mood and sleep, and — when you're ready — we start bringing the tablets down very slowly, with you in charge of the pace. I'll see you again in two weeks. Can we try that together?"
Key principle: NICE NG215 (medicines associated with dependence or withdrawal symptoms) emphasises shared decision-making: explain the reasons for reducing, agree a withdrawal plan the person understands, reduce gradually at a pace they can tolerate, and do not stop abruptly. Neil does not have to agree to a taper today — "not yet" with a review date is a legitimate outcome, provided the dose does not go up and the safety measures (naloxone, alcohol, combination) are in place now.
7B — Why treatment matters: goals tailored to Neil
120 mg
OME per day — do not escalate towards this: harm increases substantially without increased benefit (local high-dose opioid guidance). Neil's dose sits in this zone: the argument for reducing, not escalating
>3 months
Long-term opioid use for non-cancer pain beyond 3 months carries increased risk of dependence and addiction, even at therapeutic doses (MHRA DSU, September 2020) — agree an end-of-treatment plan before starting
5–10%
Of the current dose every 2–4 weeks — an example starting point, not a fixed rule (site opioid protocol; NICE NG215): individualised and proportional, one drug at a time, smaller steps at lower doses; months, not weeks, and the patient sets the pace
0
Opioids for chronic low back pain; gabapentinoids and SSRIs/SNRIs/TCAs are also not to be offered for managing low back pain (NICE NG59)
Class C
Pregabalin and gabapentin became Schedule 3 controlled drugs in April 2019; packaging and leaflets are being updated to carry "may cause addiction, dependence and withdrawal reactions" (MHRA DSU, January 2026)
3 days · 32
OTC codeine and dihydrocodeine combinations: packs of no more than 32 tablets, labelled "can cause addiction — for three days' use only" (MHRA, 2009)
Neil's goals — function first, written down together
Walk to the shops / round the park — set a baseline distance and build it up weeklyA realistic step towards work (voluntary role, phased return, retraining) by 6–12 months No dose increases; slow, agreed opioid then gabapentinoid reductionTake-home naloxone at home; family know what to do Alcohol within low-risk limits, and never with the tablets at nightBetter sleep: regular wake time, less daytime napping Mood assessed and treated; no thoughts of self-harm left unexploredSame GP, booked reviews — no "lost" prescriptions, no early scripts

Record a baseline (walking distance, activities, sleep hours, PHQ-9, AUDIT-C, total OME) so progress is measured against function, not the pain score. Pain scores often barely change even when life improves — and that is still success.

Motivational language — tailored to Neil
"If I asked you what a good day would look like six months from now — not pain-free, but a good day — what would you be doing? That's what I want us to aim for."
"A lot of people who come down slowly from high doses tell me they feel clearer-headed, less tired and more like themselves — and often the pain is no worse, sometimes better. We'll go at your pace and check at every step."
"You've been carrying this for four years. You don't need to fix everything at once — just the next small step, and I'll be alongside you."
7C — Non-medication management: mechanism + evidence + target
For chronic low back pain NICE NG59 puts exercise and a return to normal activity at the centre; for chronic primary pain NG193 adds psychological therapy (exercise, ACT/CBT, and — for chronic primary pain but not low back pain — acupuncture). These are the treatments, not the consolation prize, and Neil has never been offered them.
🏃
Group exercise programme
Target: supervised programme, then 150 min/week of activity he chooses
Mechanism

Graded activity reconditions deconditioned muscles, reduces fear of movement by exposure, improves sleep and mood, and engages descending pain inhibition. "Hurt does not equal harm" becomes a lived experience rather than a slogan.

Practical

Refer to physiotherapy / an exercise-based back programme. Start below his current tolerance (pacing), increase by small fixed amounts rather than "until it hurts", and expect flare-ups — plan for them in advance. Choice of exercise matters less than doing it consistently.

NICE NG59: consider a group exercise programme for a specific episode or flare of low back pain; NG193 recommends supervised group exercise for chronic primary pain
🧠
Psychological therapy for pain (ACT / CBT)
Target: referral agreed at this visit
Mechanism

A CBT-informed approach addresses catastrophising, fear-avoidance, low mood and unhelpful beliefs about damage, while the physical component rebuilds capacity. ACT helps people pursue valued activities alongside pain rather than waiting for it to go.

Practical

Pain-management programme (usually group-based, via the local pain service or MSK service). NHS Talking Therapies can offer psychological support for coexisting depression or anxiety; many services have long-term-condition pathways. Self-management resources such as Live Well with Pain can bridge the wait.

NICE NG193: consider ACT or CBT for pain for chronic primary pain. NG59's combined physical–psychological programme recommendation was withdrawn in July 2026 (retracted evidence)
📚
Explanation & pain education
Target: Neil can explain "sensitised alarm" in his own words
Mechanism

Persistent pain reflects a sensitised nervous system more than ongoing tissue damage — the "over-sensitive alarm". Understanding this reduces threat, fear and the drive to seek stronger drugs, and makes exercise and tapering feel safe.

Practical

Use simple analogies (a car alarm that goes off when someone walks past), reassure that normal scans are genuinely good news, and give written or online resources. Revisit at each appointment — one explanation is rarely enough.

NG59: provide advice and information tailored to the person's needs, including encouragement to continue normal activities; NG193: discuss what the person thinks is causing their pain
😴
Sleep
Target: fixed wake time; no alcohol as a sleep aid
Mechanism

Poor sleep lowers pain thresholds and worsens mood; pain and alcohol fragment sleep further. Opioids themselves disturb sleep architecture and can worsen sleep-disordered breathing.

Practical

Behavioural approaches first (consistent wake time, limiting daytime naps, stimulus control; digital CBT for insomnia where commissioned). Avoid adding hypnotics — a benzodiazepine or Z-drug on top of opioids and a gabapentinoid is the combination MHRA warns can be fatal.

Hypnotics with opioids: only if no alternative (MHRA DSU, March 2020)
🍺
Alcohol reduction
Target: ≤14 units/week spread over 3+ days; none with night-time doses
Mechanism

Alcohol adds to opioid and gabapentinoid respiratory depression, disrupts sleep, worsens mood, and increases paracetamol liver risk. Reducing it is one of the quickest ways to make Neil safer today.

Practical

AUDIT-C / AUDIT to quantify; brief intervention; if dependent drinking, refer to the local drug and alcohol service and do not stop alcohol abruptly without assessment (withdrawal risk). UK Chief Medical Officers' low-risk guideline: no more than 14 units a week, spread over three or more days.

Opioid + gabapentinoid + alcohol = additive respiratory depression (MHRA)
🤝
Work, activity & social prescribing
Target: one valued activity back within 3 months
Mechanism

Meaningful activity and social connection reduce the salience of pain and improve mood. Returning to some form of work is associated with better health outcomes for most people.

Practical

Social prescribing link worker for community activity, peer support or volunteering; employment support services; fit note with adjustments ("may be fit for work taking account of the following advice") if he returns. Frame each step as an experiment, not a test.

NG59: promote and facilitate return to work or normal activities of daily living
Not recommended for Neil's low back pain (NICE NG59): acupuncture; belts or corsets; foot orthotics; traction; ultrasound, TENS or interferential therapy; spinal injections (for non-specific low back pain). Radiofrequency denervation is a specialist option only for selected people with suspected facet-joint pain after a positive diagnostic block. Offering these instead of rehabilitation delays the treatments that work.
7D — Prescribing guide: which guideline, which drug, which pain
There is no single "analgesic ladder" for primary care. The WHO ladder was designed for cancer pain. For non-cancer pain, the drug decision follows the condition-specific guideline: NICE NG59 (low back pain and sciatica), NG226 (osteoarthritis), CG173 (neuropathic pain) and NG193 (chronic primary pain), with opioid stewardship from Opioids Aware and NG215, and safety warnings from MHRA. Doses: per SPC unless stated.
SituationOffer / considerDo not offer / avoidSource & notes
Acute low back painOral NSAID at the lowest effective dose for the shortest time, after GI/renal/CV/liver risk assessment and with gastroprotection where indicated. Weak opioid (± paracetamol) only if an NSAID is contraindicated, not tolerated or ineffective.Paracetamol alone. Gabapentinoids, antiepileptics, SSRIs/SNRIs/TCAs for managing low back pain.NICE NG59. Keep any weak opioid short, with a stop date and a laxative.
Chronic low back pain (Neil)Exercise programme; ACT/CBT for pain via NG193 if chronic primary pain features. Oral NSAID may be considered (lowest dose, shortest time, risk-assessed).Opioids. Gabapentinoids. SSRIs/SNRIs/TCAs for the back pain itself. Paracetamol alone.NICE NG59. Coexisting depression is treated per NICE NG222 — an antidepressant is appropriate for depression.
SciaticaExercise and stay active. NSAIDs: NG59 advises awareness of the risk of harm and limited evidence of benefit in sciatica — if used, lowest dose, shortest time, risk-assessed. No NG59 recommendation for or against antidepressants (no evidence). Consider epidural injection of local anaesthetic + steroid for acute and severe sciatica via specialist services.Gabapentinoids, other antiepileptics, oral corticosteroids or benzodiazepines (no evidence of benefit, evidence of harm); opioids for chronic sciatica.NICE NG59 (2020 update) — sciatica drug advice now sits in NG59 rather than CG173; gabapentinoids are excluded for sciatica even though CG173 lists them for other neuropathic pain. See the sciatica case.
OsteoarthritisTopical NSAID first for knee OA (consider for other joints). Then oral NSAID at the lowest effective dose for the shortest time, with a PPI. Intra-articular steroid for short-term relief to support exercise.Paracetamol and weak opioids not routinely (only infrequently, short term, when all else contraindicated/ineffective). Strong opioids — do not offer.NICE NG226 (2022). Exercise and weight management are core for everyone.
Neuropathic painChoice of amitriptyline, duloxetine, gabapentin or pregabalin; switch rather than stack if ineffective or not tolerated. Carbamazepine for trigeminal neuralgia.Tramadol only as acute rescue; do not start morphine or other opioids in non-specialist settings without specialist advice.NICE CG173. Gabapentinoids: controlled drugs; respiratory depression warnings (MHRA 2017, 2021).
Chronic primary painExercise, ACT/CBT, acupuncture (within the conditions set in NICE NG193). Consider an antidepressant (amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine or sertraline) for adults 18+, after discussion, even without depression.Do not start: paracetamol, NSAIDs, opioids, gabapentinoids and other antiepileptics, benzodiazepines, antipsychotics, ketamine, local anaesthetics (topical or intravenous), corticosteroid or local anaesthetic/corticosteroid trigger-point injections.NICE NG193. If already on one of these, review and make a shared plan to continue (if helping with acceptable harm) or reduce and stop.
Acute nociceptive pain (injury, post-op, dental)Paracetamol and/or NSAID (topical for localised soft-tissue pain); a short opioid course with a stop date if needed.Open-ended opioid repeats; codeine in under-12s; codeine for tonsillectomy/adenoidectomy for OSA in under-18s.MHRA DSU July 2013 (codeine in children); SPC for doses.
Cancer / palliative painRegular analgesia titrated to effect including strong opioids; breakthrough doses; laxatives; specialist palliative care input.The non-cancer ceilings on this page do not apply in the same way.NICE CG140 (opioids in palliative care) and the site palliative pain protocol.
Neil's taper — worked principles (site opioid protocol)
  • Count the real dose — convert every opioid to total OME using Opioids Aware guidance; ask what he actually takes.
  • One drug at a time. Agree an individualised, proportional reduction — for example about 5–10% of the current dose every 2–4 weeks as a starting point, not a fixed rule (NICE NG215) — modified-release/patch first, keeping any immediate-release doses few and countable, with progressively smaller decrements at lower doses.
  • Hold, don't reverse at difficult times; never go back up more than one step.
  • Pre-warn about withdrawal — sweats, yawning, cramps, restless legs, anxiety, diarrhoea — beginning within hours to days of a cut; duration and severity vary, and during a prolonged taper symptoms can last weeks or months (NICE NG215). Withdrawal and recurrence of the underlying pain can overlap — assess before deciding.
  • Gabapentinoid: taper gradually too (withdrawal includes anxiety, insomnia, sweating and, rarely, seizures); do not stop abruptly. Which drug first is a shared decision — the one with least benefit or most harm is a sensible start.
  • Loss of tolerance: warn that after a reduction or a gap, returning to his old dose could be fatal.
Safety measures to put in place today
  • No escalation of opioid or gabapentinoid; no new sedatives.
  • Take-home naloxone — consider for anyone on high-dose opioids, with CNS-depressant co-prescribing, alcohol misuse or previous overdose (site protocol). Show the family how to use it; it does not replace calling 999.
  • Supply controls — one prescriber, one pharmacy, shorter intervals (e.g. weekly or fortnightly) if he runs out early; no early or "lost" replacement scripts without review.
  • Alcohol — brief intervention now; never drink with night-time doses.
  • Mood and risk — PHQ-9 and a direct suicide question; if risk, limit quantities held at home and involve crisis/mental-health services.
  • Laxative — review constipation; stimulant ± osmotic rather than bulk-forming.
  • Driving — advise not to drive if drowsy or after dose changes; record it.
7F — Drug reference cards: the analgesics GPs actually prescribe
Topical NSAIDs
Ibuprofen gel · diclofenac gel · ketoprofen gel
✓ First drug for knee OA
First-line (localised)Dose per SPC and local formulary
✓ Prefer when
Knee osteoarthritis — offer before any oral analgesic (NICE NG226); consider for OA of other joints
Localised musculoskeletal or soft-tissue pain, especially where oral NSAIDs are unsafe (older age, CKD, GI or CV risk)
✗ Avoid / caution
Broken or inflamed skin; NSAID hypersensitivity
Ketoprofen: photosensitivity — avoid sun exposure of treated area
⚠ Side effects
Local skin reactions; systemic effects are much less than with oral NSAIDs
🔬 Monitor
Benefit at 2–4 weeks; continue only if it helps; combine with exercise
💬 Counselling

"Rub a small amount into the sore joint, as directed on the pack, and wash your hands afterwards. It works best alongside the exercises, not instead of them."

SCA phrase: "For your knee, the safest and most effective tablet-free option is an anti-inflammatory gel — it works locally with far fewer side effects than tablets."

Oral NSAIDs
Naproxen · ibuprofen (preferred) · COX-2 inhibitors (selected)
Consider — lowest dose, shortest time
Risk-assessedDose per SPC and local formulary
✓ Prefer when
Low back pain (NICE NG59) and OA after topical treatment (NG226) — at the lowest effective dose for the shortest time
Naproxen (up to 1000 mg/day) or low-dose ibuprofen (up to 1200 mg/day) are preferred for lower cardiovascular risk (MHRA Drug Safety Update, October 2012 and June 2015)
Offer a PPI with an oral NSAID for OA (NG226); give gastroprotection when GI risk factors exist — e.g. age 65+, previous ulcer/bleed, anticoagulant, antiplatelet, SSRI or corticosteroid co-prescription
✗ Avoid if
Active peptic ulcer or GI bleed; severe heart failure; NSAID-exacerbated asthma/hypersensitivity
Diclofenac and COX-2 inhibitors: contraindicated in established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease and congestive heart failure (MHRA, 2013 for diclofenac)
CKD (avoid in significant or unstable renal impairment); "triple whammy" with ACE inhibitor/ARB + diuretic (AKI risk); anticoagulants; pregnancy — per SPC
⚠ Side effects
Dyspepsia, peptic ulceration and bleeding; fluid retention, raised BP, heart failure exacerbation; AKI; small increase in thrombotic risk
🔬 Monitor
eGFR, BP and GI symptoms before starting and periodically if continued; review need at each prescription; sick-day advice (pause if dehydrated/vomiting)
💬 Counselling

"Take with food, for as short a time as you can. Stop and tell us if you get indigestion, black stools, ankle swelling, or if you're being sick or can't keep fluids down."

SCA phrase: "Before I prescribe an anti-inflammatory I need to check your kidneys, blood pressure and stomach risk — and I'll add a stomach-protecting tablet."

Paracetamol
Tablets · soluble · combination products (beware duplication)
Limited role in chronic pain
Acute painDose per SPC and local formulary — weight-adjusted
✓ Prefer when
Short-term acute nociceptive pain, alone or with an NSAID
Not for chronic primary pain (NG193: do not start); not alone for low back pain (NG59); not routinely for OA (NG226)
✗ Caution
Adults under 50 kg and people with risk factors for hepatotoxicity (chronic alcohol excess, malnutrition, low body weight, hepatic impairment) — reduce the dose per SPC
Hidden duplication: OTC cold remedies and co-codamol also contain paracetamol
⚠ Side effects
Few at therapeutic doses; liver injury in overdose, including staggered or cumulative overdose
🔬 Monitor
Review benefit — stop standing repeats that aren't helping; LFTs if alcohol excess or liver disease
💬 Counselling

"Check every packet you buy — many cold and flu remedies contain paracetamol too. Never take more than the label or I say, even when the pain is bad."

SCA phrase (Neil): "With the amount you're drinking, I'd want to be careful with paracetamol too — and for long-term back pain it doesn't add much anyway."

Weak opioids — codeine & dihydrocodeine
Codeine · co-codamol 8/500, 15/500, 30/500 · dihydrocodeine
Short courses only
Time-limitedDose per SPC and local formulary
✓ Prefer when
Acute low back pain only if an NSAID is contraindicated, not tolerated or ineffective (NG59); short acute pain with a stop date
✗ Avoid if
Codeine: children under 12; under-18s having tonsillectomy/adenoidectomy for obstructive sleep apnoea; known CYP2D6 ultra-rapid metabolisers; breastfeeding (MHRA DSU, July 2013). Not recommended in 12–18-year-olds with breathing problems
Chronic low back pain (NG59: no opioids); co-prescribed benzodiazepines/gabapentinoids; alcohol; respiratory disease
⚠ Side effects
Constipation, nausea, drowsiness; dependence with regular use; medication-overuse headache; variable effect because codeine needs CYP2D6 activation
🔬 Monitor
Stop date on the prescription; laxative; ask about OTC codeine purchases (pharmacy packs limited to 32 tablets, "for three days' use only" — MHRA 2009)
💬 Counselling

"This is for a few days only while the worst settles. It can cause addiction if taken regularly for long. Don't drive if it makes you drowsy, and take the laxative I've given you."

SCA phrase: "I'll give you a small supply with a clear stop date — these are for a short spell, not long term."

Tramadol
Immediate-release capsules · modified-release · co-formulations
⚠ Not "safe-lite"
Controlled drugDose per SPC and local formulary
✓ Place
Acute rescue only in neuropathic pain (CG173); otherwise avoid in chronic pain
Schedule 3 Class C controlled drug since June 2014 (prescription requirements and 30-day supply guidance apply)
✗ Avoid if
Epilepsy or seizure risk; taking SSRIs/SNRIs/TCAs/MAOIs (serotonin syndrome) — directly relevant if Neil starts an antidepressant
Older people (confusion, falls, hyponatraemia); co-prescribed CNS depressants; history of misuse
⚠ Side effects
Nausea, dizziness, seizures, serotonin toxicity, dependence with a marked withdrawal syndrome
🔬 Monitor
Interaction check at every new prescription; include in total OME calculation; taper, don't stop abruptly
💬 Counselling

"Tramadol is a proper opioid and can cause dependence. It also reacts with some antidepressants, so tell any doctor or pharmacist you're taking it."

SCA phrase: "Tramadol isn't a gentler option — it has the same dependence risks as other opioids plus some of its own, so I wouldn't switch you to it."

Strong opioids
Morphine MR/IR · buprenorphine patch · oxycodone · fentanyl patch (specialist)
✗ Not for chronic LBP
StewardshipPer SPC / Opioids Aware
✓ Place
Cancer and palliative pain; selected nociceptive pain as a time-limited trial with written functional goals and an agreed exit (site opioid protocol)
Specialist advice before escalating towards about 120 mg/day OME (local high-dose opioid guidance)
✗ Do not
Offer for chronic low back pain (NG59), start for chronic primary pain (NG193), or offer strong opioids for OA (NG226)
Co-prescribe with benzodiazepines unless no alternative (MHRA DSU, March 2020); caution with gabapentinoids and alcohol
Stop abruptly after regular use; switch opioids without dose reduction for incomplete cross-tolerance
⚠ Side effects
Constipation (persistent), sedation, respiratory depression, tolerance, opioid-induced hyperalgesia, hypogonadism, falls, dependence and addiction
🔬 Monitor
Function against goals, total OME, bowels, sedation, mood, alcohol, early requests; testosterone if symptoms; review at least 6-monthly once stable
💬 Counselling

"Opioids can cause dependence and addiction even at prescribed doses (MHRA 2020). Never mix with alcohol or sleeping tablets, keep them locked away, never stop suddenly, and return any spares to the pharmacy."

SCA phrase (Neil): "Going higher would add risk without adding relief. What I can offer is a slow, supported way down, alongside the treatments that do help back pain."

Gabapentinoids
Pregabalin · gabapentin
✗ Not for back pain · neuropathic only
Class C CDDose per SPC and local formulary (renal adjust)
✓ Place
Neuropathic pain — one of the four first-line options (CG173), e.g. post-herpetic neuralgia, painful diabetic neuropathy
✗ Do not
Offer for low back pain or sciatica (NG59); start for chronic primary pain (NG193)
With opioids, alcohol or other CNS depressants; respiratory or neurological disease; renal impairment; age over 65 — severe respiratory depression reported (MHRA DSU gabapentin October 2017; pregabalin February 2021)
History of substance misuse — Schedule 3 controlled drugs since April 2019
⚠ Side effects
Dizziness, sedation, weight gain, cognitive effects, falls; dependence and withdrawal — packs to carry "may cause addiction, dependence and withdrawal reactions" (MHRA DSU, January 2026)
🔬 Monitor
Benefit vs harm at each review; eGFR for dose; agree a plan for reducing or stopping before starting (MHRA 2026); taper gradually — never stop abruptly
💬 Counselling

"This medicine isn't recommended for back pain, and with your other tablets and alcohol it adds to the risk of slowed breathing. We'll bring it down gradually so you don't get withdrawal."

SCA phrase: "Pregabalin is a nerve-pain medicine — it isn't recommended for back pain, and it's one of the things making your current mix risky."

Antidepressants used in pain
Duloxetine · amitriptyline · SSRIs (citalopram, fluoxetine, paroxetine, sertraline)
Depends on the pain type
Indication-specificDose per SPC and local formulary
✓ Prefer when
Chronic primary pain, adults 18+: consider amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine or sertraline after discussion — even without depression; most use is off-label (NG193)
Neuropathic pain: amitriptyline or duloxetine (CG173)
Depression coexisting with chronic pain — treat per NICE NG222
✗ Do not / caution
Not for managing low back pain itself (NG59: do not offer SSRIs, SNRIs or TCAs)
Amitriptyline: cardiac disease/arrhythmia, overdose toxicity (important where suicide risk), falls and anticholinergic burden in older people. Duloxetine/SSRIs: serotonin syndrome with tramadol; bleeding risk with NSAIDs (gastroprotection)
⚠ Side effects
Nausea, sweating, insomnia or sedation, dry mouth; discontinuation symptoms if stopped abruptly; early agitation or suicidal thoughts in younger adults
🔬 Monitor
Review early after starting (within 1–2 weeks if suicide risk); benefit on function, sleep and mood; stop if no benefit
💬 Counselling

"This isn't because I think the pain is in your head. These medicines can help sleep, mood and how the nervous system handles pain. It takes a few weeks to judge."

SCA phrase (Neil): "Your mood matters in its own right. If the questionnaire shows depression, an antidepressant is a reasonable option, and some have the bonus of helping with pain."

Take-home naloxone
Intramuscular kit · intranasal spray
✓ Harm reduction
SafetyAs per product / SPC
✓ Consider when
High-dose opioids; opioid + benzodiazepine/gabapentinoid/alcohol; previous overdose; misuse; after a taper or gap (lost tolerance) — site opioid protocol
✗ Limitations
Short-acting — the effect can wear off before the opioid's; always call 999 and stay with the person
Precipitates acute withdrawal in dependent patients — expected, and not a reason to withhold it
⚠ Practicalities
Available from drug and alcohol services and some pharmacies as well as on prescription; check local arrangements
🔬 Monitor
Check kit is in date and family know where it is at each review
💬 Counselling

"This is like a fire extinguisher — I hope it's never needed. If you can't be woken or your breathing is very slow, whoever is with you calls 999 and uses this."

SCA phrase: "Offering naloxone isn't me expecting the worst — it's a standard safety step for anyone on your combination of medicines."

7G — Psychosocial impact: work, driving, family & identity
🤝
Changing the medication changes a life — plan for the knock-on effects
🚗
Driving and the law

Driving with certain specified drugs (including morphine) above set blood limits, or while impaired by any drug, is an offence; there is a medical defence if the medicine is taken as directed and driving is not impaired. Advise no driving when drowsy, on starting or changing a dose, during noticeable withdrawal, or after alcohol. Patients do not usually need to tell the DVLA simply because they take prescribed opioids, but must if a medical condition or the medication affects their ability to drive safely (check DVLA guidance).

"On the days after each dose change, or if you feel foggy or drowsy, please don't drive. If you ever feel the tablets affect your driving, you mustn't drive — and we should talk about it."
💼
Work and benefits

A taper and a rehabilitation programme can feel like a threat to a benefits claim or to "proof" of disability. Be explicit that the aim is his wellbeing, that fit notes and reports will reflect his condition honestly, and that improvement at his own pace is not a trap. Employment support services and occupational health can help with a phased return.

"Getting you more active isn't about pushing you back to work before you're ready. It's about you getting more of your life back — and when you feel ready, there's support for the next step."
👪
Family and carers

The family live with the effects of both the medication (sedation, irritability) and the taper (withdrawal, flare-ups). Involving a partner helps with pacing, storage, naloxone and noticing low mood. Securely store all opioids and gabapentinoids — one opioid tablet can be dangerous to a child.

"Would you like your partner to know the plan? It helps to have someone who understands that a rough few days after a reduction is withdrawal settling, not the pain getting worse."
👤
Identity and stigma

Being on opioids can bring stigma — "addict", "drug-seeker" — which patients often feel keenly. Separate physical dependence (an expected effect of long-term use) from addiction, and use neutral language in the notes and at the pharmacy. Neil's identity as someone who worked and was active is a resource to draw on.

"Your body being used to these tablets is a normal effect of taking them for years — it doesn't make you an addict. We'll reduce them carefully because that's how your body stays comfortable."
7H — Follow-up schedule
1
Today — safety and agreement

No dose increase. Total OME recorded. Naloxone supplied and explained. Alcohol brief intervention. PHQ-9, GAD-7 and a direct suicide question. Referrals: exercise-based programme, plus psychological therapy for pain (ACT/CBT) or a pain-management programme; drug and alcohol service if dependent drinking or addiction features. Agree when the taper might start (today or at the next visit) and write down functional goals.

Naloxone + combination riskGoals recorded
2
2 weeks — first step

Same clinician. How has he been? First agreed opioid reduction step (e.g. 5–10% of the current dose) and how it was tolerated; withdrawal vs pain explained again. Alcohol, sleep, mood. Any new red flags. Prescription interval and pharmacy confirmed.

Taper step 1Mood / risk
3
Every 2–4 weeks — the taper rhythm

Next step if tolerated; hold if a life event or a bad fortnight, never go back up more than one step. Has the exercise or programme started — what got in the way? Treat depression if confirmed; review any antidepressant. Celebrate function gained (distance walked, activities resumed).

Function before pain scoreHold, don't reverse
4
3 months — review the whole plan

Function against baseline; PHQ-9; AUDIT-C; OME now vs start. When the opioid is lower, plan the gabapentinoid reduction (or vice versa). Consider pain service advice if the taper has stalled at a high dose, or drug service if addiction features emerge.

Specialist if stalled
5
6–12 months and annually

Every analgesic still prescribed has a documented functional benefit. Red flags re-screened. Testosterone if symptoms on long-term opioids. Driving advice re-recorded. Relapse plan for flares that does not involve restarting high-dose opioids.

Re-screen red flagsAnnual medication review
7I — Monitoring: function, safety and the taper

Memory rule — review every analgesic against "FORMS"

Function gained (the real outcome) · OME total and how he actually takes it · Red flags and risk (new pathology, mood, suicide) · Mixing (alcohol, benzodiazepines, gabapentinoids, OTC codeine) · Side effects (bowels, sedation, falls, hormones).

Medication / targetMonitorTimingAction threshold
Opioids (any)Total OME; function vs goals; sedation; bowels; early requestsEach taper step; at least 6-monthly once stableAbout 50 mg/day OME → heightened review; approaching ~120 mg/day → specialist advice; no functional benefit → agreed, individualised taper; aberrant use → name it, shorter supply intervals, drug service
GabapentinoidsBenefit, sedation, dizziness, falls; eGFREach reviewNot indicated for back pain → shared plan to taper; reduced eGFR → dose adjustment per SPC
Oral NSAIDseGFR, BP, GI symptoms, PPI coverBefore starting; periodically if continuedFalling eGFR, uncontrolled BP, GI bleeding signs → stop; ACE inhibitor/ARB + diuretic → avoid or monitor closely
ParacetamolWeight, alcohol intake, LFTs if riskAt prescribing and reviewUnder 50 kg or hepatotoxicity risk → reduced dose per SPC; not helping → stop the repeat
Mood and riskPHQ-9, GAD-7, direct suicide questionBaseline, each visit during taperSuicidal ideation → same-day risk assessment, reduce quantities at home, crisis team as needed
AlcoholAUDIT-C / AUDITBaseline, 3-monthlyHigher-risk drinking or dependence → brief intervention / specialist referral; assessed withdrawal plan
Endocrine (long-term opioids)Symptoms; testosterone in menAnnually or if symptomaticLow → endocrine advice and a further reason to taper
Red flagsNew/changed pain, neurology, weight loss, fever, bladder/bowel/saddle symptomsEvery visitCauda equina symptoms → emergency same day; other red flags → urgent assessment per NICE NG12 / local pathways
7J — Safety-netting: exact phrases, RAG marking and danger zones
🔴 Overdose signs — 999
"If you're ever so drowsy you can't be woken, or your breathing becomes very slow, noisy or stops, or your lips go blue — whoever is with you must call 999 and say 'possible opioid overdose', use the naloxone, and stay with you."
🍺 Never mix
"Please don't drink alcohol at the same time as these tablets, and don't take anyone else's tablets or anything for sleep or nerves on top. Together they can stop your breathing."
⏸️ Withdrawal isn't the pain returning
"For a few days after each reduction you might feel sweaty, restless, achy or have an upset stomach. That's your body adjusting, and it usually eases as you settle at each new dose. If it's too much, call me — we'll hold the dose, not go back up."
🔒 Lost tolerance
"Once we've lowered the dose, your body gets less used to it. Never go back to your old dose or take extra you've saved — it could be dangerous even though you used to take that much."
🚨 Red flags in the back
"If you get numbness around your bottom or between your legs, new trouble passing urine or controlling your bladder or bowels, or weakness in both legs — that's an emergency: call 999 or go to A&E straight away. New fever, weight loss or pain that's getting steadily worse at night — contact us the same day."
😔 Mood
"If you ever feel you can't go on, or have thoughts of harming yourself, please call us the same day, NHS 111 (option 2 for mental health where available), Samaritans (number on their website), or 999 if you're in danger."
Tasks — safety-netting
🟢
Overdose signs and 999 explained; naloxone offered and demonstrated; alcohol/sedative mixing addressed; withdrawal vs pain distinguished; lost-tolerance warning; cauda equina and other red flags; mood/suicide safety-net; driving advice; review booked with same clinician
🟠
Generic "come back if worse"; red flags given but no overdose or combination advice; naloxone mentioned but not arranged; no lost-tolerance warning; follow-up vague
🔴
No safety-net; dose escalated or stopped abruptly without advice; high-risk combination not mentioned; mood/suicide risk not addressed; no follow-up arranged
Relating to Others — safety-netting
🟢
Delivered as care, not suspicion; checks understanding (teach-back); involves family with consent; leaves Neil feeling supported rather than policed
🟠
Correct content but delivered as a list; no check of understanding; family not considered
🔴
Warnings delivered as accusation ("you're at risk of addiction"); patient left feeling blamed or abandoned
Increasing the opioid "to keep him on side"
No opioids for chronic LBP (NG59); towards ~120 mg/day OME harm rises substantially without benefit (local high-dose opioid guidance). Validate, decline, offer a real alternative.
Stopping everything today
Abrupt cessation causes withdrawal, drives illicit use and, after lost tolerance, overdose. Agree an individualised, proportional taper — e.g. 5–10% of the current dose every 2–4 weeks as a starting point (site protocol; NG215).
Adding a benzodiazepine or Z-drug for sleep or anxiety
Opioid + benzodiazepine: potentially fatal respiratory depression — only if no alternative (MHRA, March 2020). Use behavioural sleep strategies.
Switching to tramadol as a "milder" option
Tramadol is a Schedule 3 controlled drug with dependence, seizure and serotonin-syndrome risk — especially with an SSRI/SNRI.
Starting an antidepressant "for the back pain"
NG59 says do not offer SSRIs/SNRIs/TCAs for low back pain. Assess mood; treat depression in its own right if present (NG222).
Attributing every new symptom to "chronic pain"
Re-screen red flags at every visit — cauda equina, infection, malignancy (NG12 for age-related criteria), fracture.
🎓 SCA Checkpoint — Step 7TasksRelating to OthersGlobal Skills
A plan that scores
"Here's the plan: rather than more opioids, I'll get you physiotherapy and a pain programme, support for your mood and drinking, and we'll ease the strong medication down slowly together — no sudden stops. We'll aim for what you can DO, like getting back to walking and work. I'll give you naloxone for safety, and I'll keep seeing you throughout."
Deductions
  • Escalating opioids / abrupt stopping / abandoning the patient
  • No non-drug therapies; ignoring mood/sleep/alcohol
  • No functional goals / no naloxone / no review
Analgesia in Primary Care — SCA Consultation Scorecard
Name the pain type · WHO ladder vs NG193 · opioid stewardship · deprescribe with support · the difficult conversation
0/ 33 pts
🌐
Global Skills
Structure, language, responsiveness
0/7
✓
Tasks
Clinical reasoning, prescribing, management
0/15
🤝
Relating to Others
Communication, rapport, shared decisions
0/11
RAG Self-Assessment
🔴 Red
Escalates opioids; OR refuses bluntly/abruptly stops/abandons; pain type/function/risk not assessed; no alternatives; red flags/overdose missed
🟠 Amber
Validates; names pain type; declines escalation; alternatives/deprescribing vague; risk/mood partial; ICE partial
🟢 Green
Validates + names pain type; declines escalation with NG193 therapies + supported deprescribing; high-risk combo + naloxone; treats mood/sleep/alcohol; functional goals; ICE all three; no abandonment
011172533
Fail
Borderline
Pass
Strong pass
📋
Complete the checklist to see your score and feedback
"Doc, I've come because my back's no better — the tablets still don't touch it. I need a stronger dose. I can't live like this, and nobody seems to take my pain seriously."
Who you are

Neil Brandon, 49. Four years of chronic low back pain; scans normal; no red flags. You're on increasing opioids (a high dose now) plus a gabapentinoid, and you want a stronger dose because the pain "still doesn't touch it". Despite all the medication you're worse — stopped work and exercise, sleep badly, mood is low, and you drink more than you used to. You're frustrated and feel dismissed by doctors, and frightened you won't cope without more medication. You've never been offered exercise therapy, psychological support, or a proper explanation of your pain.

Hidden concerns (reveal if explored)

Not being believed (main): you feel nobody takes your pain seriously; validation changes everything.

Fear of coping without medication: you're scared of withdrawal and worse pain — reassurance about a slow, supported reduction helps.

Low mood / drinking: you'll admit these if asked compassionately.

Clinical details if asked
  • Chronic low back pain 4 years; normal imaging; no red flags (no new severe pain/leg weakness/bladder-bowel change/weight loss/fever)
  • High-dose opioids + gabapentinoid; function worse despite them; drowsy at times
  • Drinking more than before; low mood, poor sleep; no current plan to harm yourself
  • Never offered physio/psychological therapy/pain programme or a clear explanation
Reactions at key moments
  • If refused bluntly with no validation/alternative: you get angry/upset, feel dismissed.
  • On "your pain is real and not your fault": you soften, feel heard.
  • On the honest explanation (opioids don't help long-term pain): sceptical but listen if validated.
  • On a supported, slow reduction + real therapies: anxious but willing if not abandoned.
  • Challenge line: "So you're refusing to help me and just taking my tablets away?"
"So you're saying no to a stronger dose and you want to take my tablets off me? Great — another doctor who doesn't believe me and won't help."

Resolution: Neil is well served if the GP: (1) validates that his pain is real and that he's not to blame; (2) names the pain type (chronic primary pain) and explains honestly that escalating opioids/gabapentinoids provide little benefit and cause harm (worsening function/mood, dependence, overdose — heightened by the alcohol and the drug combination); (3) declines to escalate while offering the evidence-based alternatives (NG193 with NG59 for back pain: exercise, return to normal activity, and ACT/CBT for pain under NG193) and treating his mood (an antidepressant if depression is confirmed), sleep and alcohol; (4) plans a gradual, supported, collaborative deprescribing — never abrupt — with functional goals, take-home naloxone and a safety-net, and does not abandon him. He disengages if refused bluntly, abruptly stopped, or left without validation or an alternative.

🏥
Clinic Quick Reference
Analgesia in Primary Care — Clinical Decision Framework
Pain type · WHO ladder vs NG193 · opioid stewardship
▼expand
🔍 1 — Name the pain type

Nociceptive (acute): WHO ladder, time-limited — paracetamol ± topical/oral NSAID (cautions), short opioid course with a stop date. Neuropathic: amitriptyline/duloxetine/gabapentinoid (not standard analgesics). Chronic primary pain (NG193): exercise, CBT/ACT, acupuncture, consider antidepressant; AVOID opioids/gabapentinoids/NSAIDs/paracetamol. Cancer: WHO ladder + palliative care.

⚖️ 2 — Stewardship & deprescribing

Opioids: little benefit, much harm in chronic non-cancer pain; don't escalate (esp. towards 120mg OME). Gabapentinoids = controlled drugs; never co-prescribe casually with opioids; opioid+gabapentinoid+alcohol = overdose risk → naloxone. Deprescribe gradually, collaboratively, with support; treat mood/sleep/alcohol; set functional goals; re-screen red flags; don't abandon.

🎓
SCA Quick Reference
Analgesia — Consultation Playbook
Validate · name the type · steward opioids · deprescribe with support
▼expand
🎯 The three pivots that pass this case
1 · Validate & name the type
The pain is real; name nociceptive vs neuropathic vs chronic primary — treatment follows the type.
2 · Don't escalate opioids
Little benefit, much harm in chronic pain; NG193 = exercise/psychological therapy/antidepressant, not opioids/gabapentinoids. Mind the overdose combo + naloxone.
3 · Deprescribe with support
Gradual, collaborative, never abrupt; treat mood/sleep/alcohol; functional goals; don't abandon.
⛔ Don't escalate opioids for chronic non-cancer pain · Don't refuse bluntly or stop abruptly / abandon the patient · Don't miss the overdose combination (opioid+gabapentinoid+alcohol) — offer naloxone · Don't mask a new red-flag cause as "chronic pain" · Validate, name the pain type, apply NG193, deprescribe with support and functional goals
Reviewed: July 2026 · citations verified against the primary sources listed